COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

CollPlant Biotechnologies (NASDAQ: CLGN), a pioneering company in regenerative and aesthetic medicine, has announced the date for its first-quarter financial results. The report will be released on Wednesday, May 28, 2025, prior to the opening of U.S. financial markets. CollPlant specializes in innovative solutions leveraging plant-derived recombinant human collagen (rhCollagen) for various applications, including tissue regeneration and medical aesthetics.

The company is at the forefront of harnessing 3D bioprinting technology to address critical needs in tissue repair, aesthetics, and organ manufacturing. One of their significant milestones includes a collaboration with Allergan, a subsidiary of AbbVie, which is a leader in the dermal filler market. This partnership, established in 2021, allows for the development and commercialization of dermal and soft tissue fillers, further demonstrating CollPlant's commitment to advancing medical solutions.

Through its proprietary plant-based genetic engineering technology, CollPlant aims to redefine how medical conditions related to tissue damage and aesthetic enhancement are approached. The upcoming financial results will be closely observed by investors and analysts, as they provide insight into the company’s growth trajectory and overall market performance.

For further inquiries, CollPlant's Deputy CEO and CFO, Eran Rotem, can be contacted directly, along with their investor relations representative, Daniel Ferry from LifeSci Advisors. This financial results announcement is an essential step for the company as it continues to innovate in a rapidly evolving market focused on regenerative healthcare solutions.

For more information about CollPlant, interested parties can visit their official website at http://www.collplant.com.

CollPlant Biotechnologies (NASDAQ: CLGN) is at a critical juncture as it prepares to report its first quarter financial results on May 28, 2025. Investors should approach this upcoming announcement with a keen awareness of the company's unique positioning within the regenerative and aesthetic medicine sector.

CollPlant specializes in innovative solutions utilizing recombinant human collagen (rhCollagen) produced through its proprietary plant-based genetic engineering technology. This distinctive approach not only separates CollPlant from competitors but also aligns with the growing demand for sustainable medical solutions. The company has made strides in collaborations, notably with Allergan, a leader in the dermal filler market, which can significantly bolster its market presence.

In the lead-up to the earnings report, investors should pay close attention to the growth metrics and any updates on ongoing projects. A solid financial report, particularly if it indicates strong sales traction from its partnership with Allergan, could instill confidence and potentially drive share prices higher. Conversely, any disappointment or missed expectations could lead to a correction given the volatility often observed with biotech stocks.

Moreover, market trends in regenerative medicine are promising. The increasing acceptance and demand for aesthetic enhancement procedures could provide a favorable backdrop for CollPlant’s offerings. Investors should monitor industry developments and any competitive advancements that could either enhance or hinder CollPlant’s market position.

In summary, while the upcoming earnings report presents an opportunity to gauge CollPlant’s financial health and operational progress, potential investors should remain vigilant about market dynamics and manage their expectations regarding share price fluctuations, particularly in response to the financial results on May 28.